Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Phase 1

ACTengine® IMA203 Combined With mRNA-4203

NCT06946225 · tracked via the Priya Life Science USA tracker
Phase
Phase 1
Started
2025-07-25
Last updated
2026-01-08

Condition(s) studied

Cutaneous MelanomaSynovial Sarcoma

Investigational drug(s) / intervention(s)

IMA203 →mRNA-4203 →

IMA203: Following non-myeloablative chemotherapy for lymphodepletion (LD) with fludarabine (FLU) and cyclophosphamide (CY), participants will receive a single infusion of IMA203 on Day 1 and adjunctive therapy with low dose interleukin (IL)-2 for up to 10 days, starting approximately 24 h after IMA203 infusion.

mRNA-4203: mRNA-4203 will be administered starting on Day 15 after IMA203 infusion at the earliest. mRNA-4203 will be given for 12 cycles (28 day cycle length); during Cycle 1 it will be given on Day 1 and Day 15 and in Cycles 2-12 it will be given on Day 1.

Study summary

This purpose of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA203 in combination with different doses of mRNA-4203. The trial includes participants with previously treated unresectable or metastatic cutaneous melanoma (CM) or synovial sarcoma (SS).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Pathologically confirmed and documented cutaneous melanoma (CM) or synovial sarcoma (SS) with unresectable or metastatic disease * HLA-A\*02:01 positive * Adequate selected organ function per protocol * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) * Life expectancy more than 5 months * CM participants who must have disease progression (resistance, toxicity) on or after at least one PD-1 inhibitor * SS participants must have received (or declined) at least one line of treatment (including SoC) and are still in need of further systemic therapy. * Female participants of childbearing potential must use adequate contraception prior to trial entry until 12 months after the infusion of IMA203 and 15 days after the last mRNA 4203 dose administration Other protocol defined inclusion criteria could apply Exclusion Criteria: * History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within the last 3 years * Pregnant or breastfeeding * Serious autoimmune disease * History of cardiac conditions as per protocol * Prior allogenic stem cell transplantation or solid organ transplantation * Concurrent severe and/or uncontrolled medical disease that could compromise participation in the study * History of hypersensitivity to cyclophosphamide, fludarabine, or IL-2 * History of hypersensitivity to mRNA-based medicines * Positive for HIV infection or with active hepatitis B virus (HBV) or active hepatitis C virus (HCV) infection * Any condition contraindicating leukapheresis * Participants with lactate dehydrogenase (LDH) greater than threshold allowed per protocol * Participants with active brain metastases prior to lymphodepletion * Concurrent treatment in another clinical trial or a device trial that could interfere with the IMA203 treatment * Participants with renal impairment AND reduced bone marrow reserve per protocol Other protocol defined exclusion criteria could apply

Primary outcome measure(s)

  • Number of participants with dose-limiting toxicities (DLTs) — one year post infusion of IMA203
    Number of DLTs will be used to determine the maximum tolerated dose (MTD) and/or recommended dose for extension (RDE) after treatment with IMA203 product in combination with mRNA-4203
  • Number of treatment emergent adverse events (AEs), AEs of special interest, serious AEs (SAEs), changes in laboratory parameters and vital signs, and frequency of dose interruptions, reductions and discontinuations — one year post infusion of IMA203
    Used to evaluate safety and tolerability of treatment with IMA203 in combination with mRNA-4203

Trial sites (4)

FacilityCityRegionStatus
University of California San Francisco San Francisco California Recruiting
Dana Farber Cancer Institute Boston Massachusetts Recruiting
Memorial Sloan Kettering Cancer Center New York New York Recruiting
MD Anderson Cancer Center Houston Texas Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06946225 on ClinicalTrials.gov ↗ ← All trials in the USA